Open Access<p>Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries</p>
Author(s) -
Edith M. Heintjes,
Irene D. Bezemer,
Daniel PrietoAlhambra,
Elisabeth Smits,
Helen Booth,
Daniel Dedman,
Ying He,
Fabian Hoti,
Minna Vehkala,
Stefan de Vogel,
Noah Jamie Robinson,
Kwame Appenteng,
Fernie J. A. Penning-van Beest
Publication year - 2020
Publication title -
clinical epidemiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.868
H-Index - 58
ISSN - 1179-1349
DOI - 10.2147/clep.s242065
Subject(s) - medicine , mirabegron , measure (data warehouse) , alternative medicine , data mining , pathology , computer science , overactive bladder
Mirabegron, indicated for the treatment of overactive bladder, is contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg). In September 2015, a Direct Healthcare Professional Communication (DHPC) letter was disseminated as an additional risk minimisation measure.